Fierce Biotech April 30, 2024
Novartis is pumping another $180 million into its radioligand plan, handing the cash to serial dealmaker PeptiDream to expand (PDF) a peptide-drug conjugate (PDC) collaboration.
Japan’s PeptiDream began working with Novartis in 2010 and, after repeatedly adding to the original deal, formed a collaboration focused on PDCs in 2019. The PDC pact positioned the partners to attach peptides to radionuclide payloads to enable targeted radiotherapy. Like antibody-drug conjugates, PDCs are designed to get drugs to cancer cells without harming healthy tissues.
Novartis paid an undisclosed upfront fee to form the original PDC pact. Now, the Swiss drugmaker has put down a further $180 million and offered up to $2.71 billion in milestones to expand the alliance.
In return, PeptiDream...
Today's Sponsors
Today's Sponsor